Interventional Radiology Imaging

What Is the Best Treatment for Multifocal, Bilobar Hepatocellular Cancer?

·
What Is the Best Treatment for Multifocal, Bilobar Hepatocellular Cancer?

A hepatologist reviews the latest multiphasic CT scan for a 64-year-old patient with known alcohol-related cirrhosis. The images confirm the team’s concern: multiple enhancing masses are present in both the right and left lobes of the liver, consistent with hepatocellular carcinoma (HCC). The largest lesion in segment VII measures 6.5 cm. Given the multifocal, bilobar nature of the disease and the patient’s underlying liver dysfunction, surgical options are off the table. The immediate question is which liver-directed or systemic therapy offers the best path forward for controlling this extensive tumor burden. This article provides a detailed clinical workflow for this specific scenario, guided by the American College of Radiology (ACR) Appropriateness Criteria, which rate Transarterial Chemoembolization as a Usually Appropriate intervention.

Who Fits This Clinical Scenario for Multifocal, Bilobar Hepatocellular Cancer?

This guidance applies to a specific subset of patients with hepatocellular carcinoma. The key inclusion criteria are a confirmed diagnosis of HCC in a patient with underlying cirrhosis, characterized by multifocal tumors distributed across both lobes of the liver, with at least one of those tumors measuring greater than 5 cm in diameter. Clinically, these patients typically fall into the Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC B). Ideal candidates for the therapies discussed here have preserved liver function (Child-Pugh class A or early B) and a good performance status (ECOG 0-1), enabling them to tolerate locoregional treatment.

This workflow is distinct from several similar-appearing but clinically different scenarios. This guidance does not apply if:

  • The patient has a solitary tumor less than 5 cm. Smaller, solitary lesions are often amenable to curative-intent therapies like percutaneous ablation or surgical resection, which are considered first-line options in that context.
  • There is evidence of vascular invasion or extrahepatic spread. The presence of tumor in the portal vein or metastatic disease outside the liver (BCLC C) fundamentally changes the treatment paradigm, typically prioritizing systemic therapies or, in select cases, radioembolization.
  • The patient has decompensated cirrhosis. Patients with poor liver function (Child-Pugh C) or poor performance status (ECOG >2) are generally not candidates for aggressive locoregional therapies due to the high risk of inducing further liver failure. Their care is often focused on medical management and supportive measures.

What Are the Therapeutic Goals in This Scenario?

For patients with multifocal, bilobar HCC too extensive for resection or ablation, the diagnosis is established, and the clinical “workup” shifts from diagnosis to therapeutic strategy. The management goals are centered on controlling the cancer, preserving organ function, and extending survival, as curative-intent therapy is not feasible upfront.

Tumor Control and Downstaging: The primary objective is to gain control over the significant tumor burden. The large and numerous tumors pose an immediate threat of progression and further compromise of liver function. An effective locoregional therapy aims to induce tumor necrosis, halt growth, and prevent the development of new lesions. In some cases, exceptional response to treatment can reduce the tumor burden to a point where a patient, previously ineligible, might be reconsidered for other treatments like transplantation—a concept known as downstaging.

Preservation of Liver Function: The patient’s cirrhosis means their functional liver reserve is already compromised. Any treatment must be carefully selected to maximize anti-tumor effect while minimizing damage to the non-cancerous liver parenchyma. This balance is critical, as iatrogenic liver injury can lead to decompensation and negate any benefit gained from tumor control.

Palliation and Survival Extension: In the context of unresectable, non-transplantable disease, the overarching goal is to extend patient survival while maintaining the best possible quality of life. The chosen therapy must be effective enough to impact the natural history of the disease but tolerable enough to be administered without causing debilitating side effects.

Why Is Transarterial Chemoembolization a Recommended Therapy for Multifocal, Bilobar HCC?

For this specific presentation, the ACR panel rates several transarterial therapies and systemic options as Usually Appropriate. Transarterial chemoembolization (TACE) is a cornerstone of treatment for this patient population due to its ability to deliver targeted, high-dose therapy directly to the tumors while limiting systemic toxicity.

The rationale for TACE is twofold. First, HCC is a hypervascular tumor that derives most of its blood supply from the hepatic artery, whereas the healthy liver parenchyma is primarily supplied by the portal vein. Interventional radiologists exploit this dual blood supply by navigating a microcatheter into the specific arterial branches feeding the tumors. Second, a combination of chemotherapeutic agents and embolic particles is injected. This achieves a high local drug concentration within the tumor and simultaneously cuts off its arterial blood supply, inducing ischemic necrosis. This targeted approach is highly effective for the large, multifocal tumors characteristic of this scenario.

Other therapies also rated Usually Appropriate include:

  • Transarterial Radioembolization (TARE): This procedure, also known as Y-90, uses microspheres loaded with a radioactive isotope (Yttrium-90) to deliver internal radiation directly to the tumors. It can be an excellent alternative to TACE, sometimes preferred for its different side effect profile or in cases of very large or infiltrative tumors.
  • Systemic Therapies: The advent of tyrosine kinase inhibitors and immune checkpoint inhibitors has revolutionized HCC management. For patients with a very high tumor burden or borderline performance status, initiating systemic therapy may be the preferred first step. Often, it is used sequentially after locoregional therapies are no longer effective.

Conversely, other common HCC treatments are rated lower for this specific scenario:

  • Percutaneous Ablation is rated Usually Not Appropriate. Ablative techniques like radiofrequency or microwave ablation are highly effective for small, solitary tumors. However, they are technically impractical and clinically ineffective for treating numerous lesions spread across both lobes, especially when one is larger than 5 cm. The risk of incomplete treatment and local recurrence is unacceptably high.
  • Surgical Liver Resection is also rated Usually Not Appropriate. Removing tumors from both lobes of a cirrhotic liver would almost certainly leave an insufficient future liver remnant, leading to postoperative liver failure and mortality.

What Is the Downstream Workflow After Transarterial Chemoembolization?

The clinical journey does not end after the first treatment. Management of intermediate-stage HCC is a dynamic process involving repeat imaging and therapy adjustments based on tumor response.

Following a TACE procedure, the first follow-up imaging—typically a multiphasic CT or MRI—is performed one to three months later. The goal is to assess treatment response using standardized criteria like the modified Response Evaluation Criteria in Solid Tumors (mRECIST), which focuses on the shrinkage of the viable, enhancing portions of the tumor.

  • If the response is positive (complete or partial): The patient is monitored, and TACE can be repeated on an as-needed basis, typically every 2-4 months. This “on-demand” strategy continues as long as the patient benefits and remains a candidate, aiming to control the disease long-term.
  • If the disease is stable: A similar strategy of continued monitoring and potential repeat TACE is often employed, with the goal of preventing progression.
  • If the disease progresses despite TACE: This is a critical juncture. Continued TACE in the face of progression offers no benefit and can harm the liver. This defines “TACE failure” or “TACE refractory” disease. The next step is a prompt transition to a different treatment modality, most commonly one of the approved Systemic Therapies. This decision should be made by a multidisciplinary tumor board.
  • If the patient is successfully downstaged: In the uncommon but ideal scenario where TACE dramatically reduces the tumor burden to within established criteria (e.g., Milan criteria), the patient may be re-evaluated for curative-intent therapies like Liver Transplantation, which was not an option at initial presentation.

Common Pitfalls to Avoid in Managing Large, Multifocal HCC

Navigating the care of patients with advanced HCC requires vigilance to avoid common clinical errors. First, carefully assess liver function before every treatment. Performing TACE on a patient with decompensated cirrhosis (e.g., new ascites, encephalopathy, or high bilirubin) can precipitate life-threatening acute-on-chronic liver failure. Second, do not neglect staging for extrahepatic disease. Before committing to liver-directed therapy, a chest CT and bone scan (if clinically indicated) are crucial to rule out metastases that would make systemic therapy the more appropriate choice. Finally, avoid the pitfall of continuing TACE indefinitely despite tumor progression. Recognizing treatment failure and escalating to the next line of therapy in a timely manner is essential for maximizing patient survival. If there is any evidence of new vascular invasion or distant metastases on follow-up imaging, escalate the case immediately to a multidisciplinary tumor board for reconsideration of the overall treatment strategy.

Related ACR Topics and Tools

This article focuses on a single, complex clinical scenario. For a comprehensive overview of all variants and management strategies, or to explore the tools used in making these decisions, the following resources are valuable.

Frequently Asked Questions

Why is liver transplantation ‘Usually Not Appropriate’ for this scenario initially?

Liver transplantation has strict eligibility criteria (like the Milan criteria) based on tumor size and number, designed to ensure the cancer has not spread microscopically. A patient with multifocal, bilobar disease and a tumor larger than 5 cm falls outside these criteria due to a high risk of post-transplant cancer recurrence. However, if treatment like TACE can successfully reduce the tumor burden to within criteria (downstaging), the patient may become a transplant candidate.

How do you choose between TACE and TARE (Y-90) since both are ‘Usually Appropriate’?

The decision is complex and often depends on institutional expertise, tumor characteristics, and patient factors. TACE is often favored for discrete, nodular tumors. TARE may be preferred for more infiltrative tumors, patients who cannot tolerate the acute effects of chemoembolization, or in some cases of portal vein involvement. The choice is best made in a multidisciplinary tumor board discussion involving interventional radiology, hepatology, and oncology.

What is the role of external beam radiation therapy (EBRT) in this scenario?

EBRT is rated ‘May be appropriate’ by the ACR. While transarterial therapies are generally preferred for multifocal disease, advanced techniques like stereotactic body radiation therapy (SBRT) can be highly effective for treating specific, dominant, or symptomatic lesions. It is sometimes used as a salvage therapy after TACE or for tumors in locations difficult to treat with transarterial methods. It can also be used for palliative purposes to control pain.

If a patient has multifocal HCC but all tumors are less than 3 cm, does this guidance still apply?

Not directly. While still multifocal, if the total tumor burden is low and all lesions are small, the patient might be considered for different approaches. TACE remains a strong option, but depending on the number and location of tumors, some centers might consider sequential percutaneous ablation. The presence of a large (>5 cm) tumor is a key factor that pushes the recommendation strongly toward transarterial therapies.

What defines ‘TACE failure’ and mandates a switch to systemic therapy?

TACE failure or refractoriness is generally defined as disease progression after two or more consecutive, technically successful TACE sessions. This includes the growth of treated tumors, the appearance of new intrahepatic lesions, or the development of vascular invasion or extrahepatic spread. Once a patient meets these criteria, continuing TACE is not recommended, and a switch to systemic therapy is the standard of care.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026